Article
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO precision oncology - 1 Jun 2023
Ganti Apar K, Rothe Michael, Mangat Pam K, Garrett-Mayer Elizabeth, Dib Elie G, Duvivier Herbert L, Ahn Eugene R, Behl Deepti, Borghaei Hossein, Balmanoukian Ani S, Gaba Anu, Li Rui, Osei-Boateng Kwabena, Thota Ramya, Grantham Gina N, Gregory Abigail, Halabi Susan, Schilsky Richard L
Abstract excerpt
PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from a cohort of patients with lung cancer and ERBB2 mutation or amplification treated with pertuzumab plus trastuzumab (P + T) are reported. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.